NCT03876028View on ClinicalTrials.gov

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2021

Conditions
Diffuse Large B-cell Lymphoma
Interventions
BIOLOGICAL

Tisagenlecleucel

Infusion

DRUG

Ibrutinib

Oral (tablets or capsules)

Trial Locations (2)

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY